https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46551 Wed 28 Jun 2023 15:39:48 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28132 Wed 11 Apr 2018 17:17:40 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:14567 Wed 11 Apr 2018 16:06:32 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17112 Wed 11 Apr 2018 13:30:06 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:23941 Wed 11 Apr 2018 11:33:41 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24481 Wed 11 Apr 2018 10:25:03 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:14945 Wed 11 Apr 2018 10:09:01 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:23231 Wed 11 Apr 2018 09:41:44 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24597 Wed 06 Apr 2022 14:05:14 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29740 Wed 06 Apr 2022 13:59:22 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49751 Tue 30 May 2023 17:07:50 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30587 Tue 01 May 2018 09:18:17 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32833 Thu 31 Oct 2019 11:12:11 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25789 Thu 17 Feb 2022 09:28:02 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:31109 Thu 13 Jan 2022 10:29:16 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49063 Thu 04 May 2023 08:07:12 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46810 Thu 01 Dec 2022 10:31:07 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:15227 Sat 24 Mar 2018 08:26:07 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:16027 Sat 24 Mar 2018 08:21:16 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17171 Sat 24 Mar 2018 08:06:31 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17250 Sat 24 Mar 2018 08:01:21 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18613 Sat 24 Mar 2018 08:01:05 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18615 Sat 24 Mar 2018 08:01:05 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20272 Sat 24 Mar 2018 07:59:53 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20493 Sat 24 Mar 2018 07:59:06 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21189 Sat 24 Mar 2018 07:52:34 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21354 n=1402) were pain free. Of those with pain, mean score was 2 (range 0-10). The majority had cancer (90%), with no significant difference between the severity of reported pain scores between cancer and nonmalignant diagnoses (P=0.27). A significant gender difference was noted, with females statistically more likely to report severe pain (χ²(3026)=5.61, p=0.018). Similarly, those <60 years were more likely to report pain χ²(3025)=3.07; p=0.022). Longitudinal changes in pain revealed the pain scores of people admitted with pain <7 always reported lower pain scores than those with severe pain on admission (90 days, F(1, 654)=55.72, p<0.001; 60 days, F(1, 1008)=48.62, p<0.001; 30 days, F(1, 1522)=60.36, p<0.001; 7 days, F(1, 1897)=15.4, p<0.001). However, pain scores of those with pain <7 on admission rose as death approached compared with those who reported severe pain. Conclusion: Even in the context of expert delivery of palliative care where pain is most likely to be optimally managed, pain continues to be a problem. Work such as this suggests that the different mechanisms that contribute to pain may influence patients' experiences even when analgesia is optimized in a specialist setting. Particular attention is needed in the future to explore the relationship between severe pain and mobility.]]> Sat 24 Mar 2018 07:51:28 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18781 Sat 24 Mar 2018 07:51:10 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21540 Sat 24 Mar 2018 07:50:24 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18532 Sat 24 Mar 2018 07:50:12 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29907 Sat 24 Mar 2018 07:40:54 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28795 15% reduction over their own baseline breathlessness intensity. Results: Eleven people had trial medication (eight males, median age 78 years (68 to 89); all had COPD; median Karnofsky 70 (50 to 80); six were on long-term home oxygen. Ten people completed day four. One person withdrew because of unsteadiness on day four. Five participants reached the 15% reduction, but only three went on to the extension study, all completing without toxicity. Conclusion: This study was safe, feasible and there appears to be a group who derive benefits comparable to titrated opioids. Given the widespread use of benzodiazepines for the symptomatic treatment of chronic refractory breathlessness and its poor evidence base, there is justification for a definitive phase III study.]]> Sat 24 Mar 2018 07:38:22 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:31110 Sat 24 Mar 2018 07:35:06 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26598 Sat 24 Mar 2018 07:33:57 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30060 Sat 24 Mar 2018 07:31:19 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28268 Sat 24 Mar 2018 07:28:35 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27058 Sat 24 Mar 2018 07:25:21 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28133 underestimate services' benefits. Observational symptom prevalence studies reported in hospice/palliative care to date have not accounted for people with long-term refractory symptoms, potentially systematically overestimating symptoms attributed to life-limiting illnesses. Cross-sectional community prevalence rates of key chronic refractory symptoms largely unrelated to their life-limiting illness reflect the likely prevalence on referral to hospice/palliative care: fatigue (up to 35%); pain (12%–31%); pain with neuropathic characteristics (9%); constipation (2%–29%); dyspnea (4%–9%); cognitive impairment (>10% of people >65 years old; >30% of people >85 years old); anxiety (4%); and depression (lifetime incidence 2%–15%; one year prevalence 3%). Prospective research is needed to establish (1) the prevalence and severity of chronic symptoms that pre-date the diagnosis of a life-limiting illness in people referred to hospice/palliative care services, comparing this to whole-of-population estimates; and (2) whether this group is disproportionately represented in people with refractory symptoms.]]> Sat 24 Mar 2018 07:24:54 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26745 Sat 24 Mar 2018 07:24:48 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:23711 Sat 24 Mar 2018 07:13:25 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:23460 Sat 24 Mar 2018 07:13:01 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48869 Mon 13 May 2024 13:50:03 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42856 Mon 05 Sep 2022 16:01:38 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45413 Fri 28 Oct 2022 12:09:54 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45431 Fri 10 Mar 2023 18:06:49 AEDT ]]>